FDA streamlining cancer diagnostics development

FDA Commissioner Scott Gottlieb Thursday announced new policies that are intended to encourage development of next-generation sequencing (NGS) technology for cancer diagnostics.

In a speech to the Community Oncology Alliance, Gottlieb presented the new guidance documents as part of broader policies that are intended to reduce the cost and improve the quality of cancer drug development. He emphasized the need to reduce drug costs and argued that lower development costs will help achieve this goal...